If Merck gets its way, it won’t be long before the prostate cancer treatment landscape looks pretty different.
Sanofi taps its chief medical officer to also become its first chief digital officer, combining the two roles inside the company.
Bayer and Geisinger aim to put contraception front and center in women's health visits, starting even before a patient sets foot in the clinic.
BMS investors have been dreading positive kidney cancer results from Merck for months. And those results might even be better than they expected.
When it comes to Xtandi in hormone-sensitive prostate cancer, Pfizer and Astellas are “really excited." And new data shows they have reason to be.
Merck’s Keytruda is duking it out with BMS' Opdivo in head and neck cancer, but Keytruda just took one step toward a big edge.
A proposed crackdown on pharma gifts and sales reps was resoundingly voted down Thursday by Philadelphia's city council.
Johnson & Johnson is the first pharma to announce it will put drug list prices directly in TV ads, self-regulating ahead of a proposed regulation.
Content is king, and it’s especially important in pharma. That’s why point-of-care agency Mesmerize has inked a deal with a top magazine publisher.
Regeneron's CEO calls Libtayo “the engine that could.” And Wednesday, those wondering, “could what?” got a glimpse at what the drug has done so far.
